Consultation with breast surgical oncology is recommended to discuss the role of subsequent surgery. Consultation with breast radiation oncology is recommended to discuss the role of further adjuvant radiation therapy, or radiation to residual chest wall/axilla.
 
Systemic therapy recommendations in the setting of locoregional recurrence should be tailored to the subtype of disease, prior treatments received, and disease free interval. Consideration of local recurrence vs. new primary breast cancer must be taken into account when providing treatment advice in this setting. Comparison to prior breast cancer pathology at multidisciplinary case conference is strongly recommended for such cases.
 
References

1. Current Oncology. Special Issue: Advances in Breast Cancer Research and Treatment. Available from: https://www.mdpi.com/journal/curroncol/special_issues/H4E6XF1219.​
• ​Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025
• Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)
• Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025
2. American Society of Clinical Oncology (ASCO). Breast cancer: ASCO guidelines. Available from: https://ascopubs.org/topics/asco-guidelines/breast-cancer
3. European Society for Medical Oncology (ESMO). Breast cancer: ESMO Clinical Practice Guidelines. Available from: https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-breast-cancer